Deep 6 AI

Deep 6 AI Inc.Founded in 2015 and headquartered in Pasadena, California, Deep 6 AI Inc. leverages artificial intelligence to streamline patient identification for clinical studies.00 mn.Deep 6 AI specializes in precision patient matching solutions designed to enhance the efficiency and effectiveness of clinical trials. Their primary offering is an AI-powered software platform that analyzes millions of patient records, including unstructured data such as physician notes and lab reports, to identify eligible study participants in real time. This technology facilitates the recruitment process by significantly reducing the time needed to find qualified patients, which typically spans from months to mere minutes. With applications in oncology and precision medicine, Deep 6 AI serves a diverse client base that includes over 8,000 clinical researchers and more than 1,100 healthcare facilities across the United States.Deep 6 AI generates revenue primarily through subscriptions and partnerships with healthcare organizations and research institutions. The company’s clients engage with its platform via a subscription model, allowing access to its comprehensive patient matching services in a B2B framework. As an illustration of their transactional structure, healthcare providers may subscribe to the platform to utilize its capabilities for clinical trial recruitment, thereby paying a recurring fee based on the level of service and data access required. This model supports clients in effectively managing their clinical trials and achieving their recruitment targets with greater precision. Specific pricing plans are aligned with the scope of services utilized, though exact figures have not been disclosed.Following its recent acquisition by Tempus AI, Inc. on March 7, 2025, which aimed to enhance its provider network and precision medicine capabilities, Deep 6 AI plans to expand its product offerings and geographic footprint. The acquisition will facilitate the enhancement of clinical trial matching and the generation of real-world evidence. Future growth strategies may include the launch of new AI-driven features and services geared towards optimizing clinical trial operations for a broader range of healthcare providers.

1. Series A

   Nov 25, 2019

   Amount

   $17M

   Investors

   Locked